Human Embryos Genetically Edited Again

For the second time, researchers use CRISPR to modify the genomes of nonviable embryos.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, ERNESTO DEL AGULA III, NHGRIUpon the one year anniversary of the first report of CRISPR being used to alter human embryo genomes, a second group has now done the same. Whereas last time, the gene-editing technique was used to fix a gene that causes β-thalassaemia, this latest attempt focused on altering an immune gene to make cells resistant to HIV infection.

“The good news is that the technique worked for this group in the same way that it did for the first group,” Peter Donovan of the University of California, Irvine, who was not involved in either study, told The Verge. “This indicates the reproducibility of the science. . . . However, this group of researchers also reproduced another finding described by the first group, namely that this type of gene editing also causes off-target effects.”

The researchers, based at Guangzhou Medical University in China, collected fertilized embryos that were not implanted because of an abnormal number of chromosomes. Publishing their results in the Journal of Assisted Reproduction and Genetics April 6, the team found limited success. As stem cell biologist Paul Knoepfler pointed out in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies